Despite the revenue growth, the company reported a net loss of $11.5 million for Q4 2025, compared to a net loss of $3.4 million in the same quarter of the previous year. The total net loss for the year was $29.7 million, consistent with the previous year's loss of $29.8 million. The company’s operating loss improved to $20.3 million in 2025, down from $32.0 million in 2024, reflecting successful cost optimization strategies.
Charlotte's Web also highlighted significant strategic developments, including a transaction with British American Tobacco (BAT) that will eliminate a substantial liability from its balance sheet and provide $10 million in new equity capital. This transaction is expected to strengthen the company's financial position and support its anticipated participation in the Centers for Medicare & Medicaid Innovations (CMMI) Medicare pilot program, which aims to provide federally authorized CBD access for senior patients.
The company is optimistic about its future, with management emphasizing the importance of operational execution and the potential for growth in the botanical wellness sector as regulatory clarity advances. The anticipated improvements in cash flow and gross margins from in-house manufacturing are expected to further enhance the company's financial health moving forward.
